India, Aug. 28 -- It has been a year of meaningful execution for Candel Therapeutics Inc. (CADL), marked by important clinical milestones, regulatory progress, and growing momentum across its pipeline.
Candel Therapeutics is developing next-generation cancer immunotherapies through two multimodal biological platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs. The company's lead candidates are Aglatimagene besadenovec, also known as CAN-2409, from its adenovirus platform, and Linoserpaturev, also known as CAN-3110, from its HSV platform.
When Did We Last Highlight CADL?
We featured CADL on our site on March 9, 2026, when it was trading at $4.79.
At the time, our report highlighted the company...